Skip to main content
. 2002 Jun;200(6):549–560. doi: 10.1046/j.1469-7580.2002.00060.x

Table 2.

Mechanisms reducing endothelial permeability

• Receptor blockade (H1 antagonists)
• Cyclic AMP elevation
• Cyclic GMP/NO (lung, large vessels)
• PKC inhibition (bovine, porcine EC)
• Rho and Rho kinase inhibition
• Inhibition of leucocyte adhesion and activation (anti-LFA-1, anti-ICAM-1)
• Inhibition of VEGF induced leakage (anti-VEGF antibodies, VEGF receptor tyrosine kinase inhibitor SU5416, Angiopoietin) (tumour vascular bed)